Episona Finishing Validation of Epigenetic Male Fertility Test With Eye on Q3 Launch | GenomeWeb

NEW YORK (GenomeWeb) – Nearing completion of a multicenter validation study, MDx startup Episona anticipates launching its sperm methylation test to diagnose male infertility and predict IVF success by the end of the third quarter this year.

Alan Horsager, co-founder, president, and CEO of Episona, told GenomeWeb that he and other co-founders started the company from an initial interest of predicting the health of future offspring — particularly the development of neurological disorders — based on analysis of a parent's sperm DNA.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.